Eric Johnston, chief equity and macro strategist at Cantor Fitzgerald, said he believes stocks are in for a tactical ...

We are entering the buy zone for the momentum factor (BATS:MTUM), , according to Eric Johnston, chief equity and macro ...

Cantor Fitzgerald announced Anchorage Digital, Copper.co will serve as collateral managers and custodians for the firm's ...

Cantor Fitzgerald currently has a $8.00 price objective on the stock. Cantor Fitzgerald also issued estimates for EVgo’s FY2025 earnings at ($0.33) EPS. Other equities research analysts also ...

Cantor Fitzgerald analyst P. Agrawal expects that the biotechnology company will post earnings of ($0.54) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock.

Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share.

Mesoblast Limited (NASDAQ:MESO – Free Report) – Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Mesoblast in a note issued to investors on Tuesday, March 4th.

Read Our Latest Stock Report on IMVT Immunovant Trading Up 2.6 % Immunovant stock opened at $20.02 on Thursday. Immunovant has a 1 year low of $17.65 and a 1 year high of $35.97. The company’s ...

Biohaven Ltd. (NYSE:BHVN – Free Report) – Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of Biohaven in a research note issued on Tuesday, March 4th.

Cantor Fitzgerald currently has a $24.00 target price on the medical equipment provider’s stock. Separately, Canaccord Genuity Group lifted their price target on shares of AxoGen from $22.00 to ...